Atovaquone-proguanil chemoprophylaxis during pregnancy: a case series and a systematic review and meta-analysis

Clicks: 16
ID: 332604
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #64 of 76 articles by views in international journal of travel medicine and global health

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Pregnant women travelling to malaria endemic areas require effective chemoprophylaxis, with limited options including atovaquone-proguanil (AP) for which safety data remain limited. Our objective was to describe the prevalences of pregnancy outcomes and major congenital anomaly (MCA) following AP chemoprophylaxis during pregnancy. METHODS: We combined a case series from the French national Teratology Information Service (CRAT) and a systematic review and meta-analysis (SRMA), including prospective pregnancies exposed to AP for chemoprophylaxis. Outcomes were prevalence of pregnancy outcomes and MCA. The case series included all pregnancies referred to the CRAT with an expected date of delivery between 2009-2025, and known outcome. The SRMA searched Medline, Embase, Cochrane databases and grey literature up to 16/09/2025. Study selection and data extraction were performed using an independent dual review process. Risk of bias was assessed with ROBINS-I. Pooled prevalences were estimated using random-effects models. GRADE was used to assess certainty of evidence. RESULTS: Our case series included 191 AP-exposed pregnancies (133 during first-trimester (T1) and 75 during second/third trimester) resulting in 85.9% livebirths (n=164), 10.0% miscarriages (n=19), 1.0% medical abortions (n=2), 1.0% stillbirth (n=2) and 2.1% elective termination (n=4). The prevalence of MCA among T1-exposed pregnancies with documented MCA status (n=110) was 3.6% (95%CI[1.0;9.0]). The SRMA included four studies, which when combined with our case series (555 AP-exposed pregnancies, 457 during T1) produced a pooled prevalence of livebirths of 80.3% (95%CI[72.3;87.2], I2=67.2%, Phet=0,047), 14.6% miscarriages (95%CI[7.3;23.9], I2=73.2%, Phet=0,024) and 2.7% for MCA (95%CI[1.2;4.8], I2=0.0%, Phet=0,45). Level of evidence was low. CONCLUSIONS: Our findings suggest that pregnancy outcomes and MCA following AP chemoprophylaxis exposure are similar to the general population prevalences, with a low level of evidence. These data strengthen the evidence supporting a reassuring safety profile, and AP may represent a reasonable option for pregnant women requiring malaria chemoprophylaxis after risk-benefit assessment.
Reference Key
openalex_W7222728277 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Juliette Condé, Bénédicte Coulm, Florence Tubach, Delphine Beghin, Valérie Pourcher, Isabelle Monier, Nathalie Lelong, Julie Tort, Mathilde Latour, Catherine Vauzelle, Élisabeth Éléfant, Jonathan L. Richardson, Agnès Dechartres, Benôıt Marin
Are you one of these authors? Claim your profile
Journal international journal of travel medicine and global health
Year 2026
DOI
10.1093/jtm/taag088
URL
https://doi.org/10.1093/jtm/taag088
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.